ImmuneAGE Bio
ImmuneAGE Bio is a pre-clinical biotech that operates a drug discovery platform targeting hematopoietic stem cells to rejuvenate the immune system, with three programs in development for aging-related immune decline, chemotherapy recovery, and bone marrow transplantation.
- Company typePrivate
- Founded2024
- HeadquartersLausanne, Switzerland
- Headcount1–10
- GTM typeB2B
- OfferingServices
ImmuneAGE Bio firmographics
Firmographics- Name
- ImmuneAGE Bio
- Website
- https://immuneage.bio
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- ImmuneAGE Bio is a pre-clinical biotech that operates a drug discovery platform targeting hematopoietic stem cells to rejuvenate the immune system, with three programs in development for aging-related immune decline, chemotherapy recovery, and bone marrow transplantation.
- Ownership category
- akta.pro rank
ImmuneAGE Bio industry classification
Industry- Product category
- Preclinical Immunology Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening) (HLAAAIAA)
- akta.pro secondary industries
- Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)
Keywords
Where ImmuneAGE Bio is headquartered
LocationHeadquarters
- HQ city
- Lausanne
- HQ country
- Switzerland
- HQ region
- Europe
Markets served
ImmuneAGE Bio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations
ImmuneAGE Bio product offering
Product offeringCore offering
ImmuneAGE Bio operates a proprietary high-throughput drug discovery platform that targets hematopoietic stem cells (HSCs) in bone marrow to rejuvenate the immune system. The platform has demonstrated 1000x expansion of HSCs and supports three preclinical therapeutic programs addressing aging-related immune decline, chemotherapy-induced immune suppression, and bone marrow transplantation.
Differentiator
Problem solved
Functional benefit
Products and services
- IA-101
- IA-201
- IA-301
Quantifiable outcome
- 1000x expansion of hematopoietic stem cells
Companies that use ImmuneAGE Bio
Customer profileSegments3 records
Ideal customer profiles1 record
ImmuneAGE Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
ImmuneAGE Bio partnerships and signals
Strategic signalScale indicators2 records
ImmuneAGE Bio competitors and assessment
Company assessmentDirect peers
- Magenta Therapeutics: Developed HSC mobilization and conditioning regimens to improve bone marrow transplant outcomes. Direct overlap with the IA-301 HSC expansion transplant-support program.
- Fate Therapeutics: Clinical-stage biotech developing iPSC-derived and HSC-derived cell therapies for cancer and immune disorders. Directly comparable in HSC and immune-cell engineering modality, with greater clinical maturity.
- Celularity: Cellular therapies derived from placenta and HSCs, with programs in immune reconstitution and transplant support. Comparable in HSC-derived therapeutic modality and ex vivo cell processing.
- Editas Medicine: CRISPR-based HSC gene editing therapies for hematologic diseases. Overlapping HSC engineering platform and ex vivo cell therapy infrastructure.
- Vor BioPharma: Focused on HSC transplantation and engineered HSC therapies for hematologic malignancies. Closely aligned in HSC engineering and bone marrow transplant indication (IA-301).
Others
- Turn Biotechnologies: Longevity-focused biotech developing mRNA-based cellular reprogramming for age-related conditions. Founded by ImmuneAGE Bio CEO Sebastian Brunemeier; relevant as an adjacent longevity platform.
Broad incumbents
- Calico Life Sciences: Alphabet-backed aging research organization with broad programs in cellular aging and immune decline. Operates in the same aging biology space with substantially larger resources and longer time horizon.
- Altos Labs: Well-capitalized (~$3B) longevity biotech pursuing cellular rejuvenation across multiple cell types, including immune cells. Operates broadly in the same aging/immunosenescence space with far greater resources.
Emerging players
- Unity Biotechnology: Clinical-stage biotech developing senolytic therapies for age-related diseases. Adjacent in the aging-immunosenescence therapeutic space but differentiated by senolytic mechanism.
- Life Biosciences: Longevity platform developing partial reprogramming and cellular rejuvenation therapies. Partial overlap with ImmuneAGE's immune-rejuvenation thesis under a broader aging program umbrella.
Market position
Customer concentration
ImmuneAGE Bio social profiles
Digital presenceImmuneAGE Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
ImmuneAGE Bio leadership team
Management profileNumber of profiles
Profiles2 records
ImmuneAGE Bio funding detail
Funding detailFunding overview
Funding rounds1 record
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ImmuneAGE Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ImmuneAGE Bio
What does ImmuneAGE Bio do?
ImmuneAGE Bio operates a proprietary high-throughput drug discovery platform that targets hematopoietic stem cells (HSCs) in bone marrow to rejuvenate the immune system. The platform has demonstrated 1000x expansion of HSCs and supports three preclinical therapeutic programs addressing aging-related immune decline, chemotherapy-induced immune suppression, and bone marrow transplantation.
Is ImmuneAGE Bio a public or private company?
ImmuneAGE Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was ImmuneAGE Bio founded?
ImmuneAGE Bio was founded in 2024. It employs 1 to 10 people.
Where is ImmuneAGE Bio based?
ImmuneAGE Bio is headquartered in Lausanne, Switzerland, in the Europe region.
Who are ImmuneAGE Bio's main competitors?
Direct peers on record are Magenta Therapeutics, Fate Therapeutics, Celularity, Editas Medicine and Vor BioPharma. Turn Biotechnologies is listed as an others. Broad incumbents are Calico Life Sciences and Altos Labs. Emerging players are Unity Biotechnology and Life Biosciences.
Does ImmuneAGE Bio have an API?
No public API is recorded for ImmuneAGE Bio.
What industry is ImmuneAGE Bio in?
ImmuneAGE Bio's product category is Preclinical Immunology Therapeutics. Its primary akta.pro industry code is HLAAAIAA, High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening), with a secondary code of HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived). Its NAICS code is 325414 and its SIC code is 2836.